Jeffrey Wade
Carcinoembryonic Antigen (CEA) is a blood test used to help diagnose and manage certain types of cancers. The test is used to measure the amount of CEA in the blood, which is a substance made by cancerous tumour cells. The CEA test is most useful after a diagnosis of a type of cancer that is known to produce CEA. The test is also used to help determine if a cancer treatment is working or if cancer has returned after treatment.
| Characteristics | Values |
|---|---|
| Full Form | Carcinoembryonic Antigen |
| Type | Blood Test |
| Purpose | Help diagnose and manage certain types of cancers |
| Use Case | Used especially for cancers of the large intestine and rectum |
| Test Time | Before, during, and after treatment |
| Normal Level | Less than or equal to 3 nanograms per milliliter (ng/mL) |
| Abnormal Level | Higher than 3 ng/mL |
| Very High Level | Higher than 20 ng/mL |
| Repercussions | Potential negative press for the insurer |
| Anti-selection | Catching people with known cancer or vague health concerns is not efficient |
Explore related products
What You'll Learn
- The carcinoembryonic antigen (CEA) blood test helps diagnose and manage certain types of cancers
- The CEA test is used especially for cancers of the large intestine and rectum
- The CEA test is not useful for diagnosing or screening the general population for cancer
- The CEA test can be used to determine if cancer has recurred after treatment
- The CEA test is capable of enough mortality reduction to yield a gain on the bottom line
The carcinoembryonic antigen (CEA) blood test helps diagnose and manage certain types of cancers
The carcinoembryonic antigen (CEA) blood test is a medical procedure used to help diagnose and manage certain types of cancers. It is particularly useful for cancers of the large intestine and rectum, also known as colorectal cancers. The test measures the amount of CEA, an antigen or protein, in the blood. Antigens are substances that are produced by cancerous tumour cells and can be released into the bloodstream.
The CEA test is typically ordered by a doctor when a patient presents symptoms suggestive of cancer. It can also be used to monitor the effectiveness of cancer treatments, such as surgery, chemotherapy, or radiation therapy. Additionally, the test can help determine if cancer has recurred after treatment. However, it is important to note that not all cancers produce CEA, and the test is not suitable for general cancer screening in healthy individuals without symptoms.
Before initiating cancer treatment, doctors may perform the CEA test to establish a baseline level of CEA in the patient's blood. This baseline is crucial because a single CEA value is often less informative than tracking multiple values over time. Repeated tests before, during, and after treatment help monitor changes in CEA levels, providing valuable insights into the effectiveness of the chosen treatment.
The CEA test is an invasive procedure that carries a risk of bleeding, bruising, or infection at the puncture site, similar to other blood tests. During the test, blood is typically drawn from a vein in the middle of the patient's arm. The healthcare provider will clean the puncture site with an antiseptic and apply an elastic band to the upper arm to enhance blood flow in the vein. Then, a needle is inserted into the vein to collect the blood sample.
While the CEA test offers valuable insights into cancer diagnosis and management, it has limitations and potential repercussions. For example, elevated CEA levels may be associated with very high mortality rates among insurance applicants, leading to potentially challenging conversations and further expensive, invasive investigations. Additionally, the test has low sensitivity, with a 50% sensitivity rate in colon cancer, which means half of patients with colon cancer may have normal CEA values. As a result, the test should be carefully considered alongside other diagnostic tools and patient-specific factors.
Medico Insurance: Is It Worth the Hype?
You may want to see also
Explore related products
The CEA test is used especially for cancers of the large intestine and rectum
Carcinoembryonic antigen (CEA) is a blood protein that is typically found in high levels in unborn babies, but healthy adults produce little to none of this protein. However, certain types of cancers, most notably colorectal cancer, can increase the levels of CEA in the blood. Therefore, a CEA test is used to measure the level of CEA in the blood or other body fluids.
The CEA test is especially useful for cancers of the large intestine (colon) and rectum. The British Journal of Cancer published results showing that CEA levels in the blood are indicative of the risk of cancer recurrence and survival rates in patients with early gastric cancer. The test is also used to monitor the response to treatment and to check for relapses and possible recurrences.
Although the CEA test is a good indicator of cancer, it is not used in isolation to diagnose cancer. It is usually combined with physical examinations and imaging tests. The CEA test is also used to evaluate how well cancer treatment is working. The test is usually carried out before treatment to set a baseline level, then again during and after treatment. If CEA levels drop during treatment, it may indicate that the treatment is working.
The CEA test is a valuable tool for cancer patients, especially those with cancers of the large intestine and rectum, as it can provide important information about the progression and treatment of the disease. However, it is important to note that the test is not perfect, and further investigations may be required to confirm the results.
Charging Insurance for Medical Help: A Guide for Medical Professionals
You may want to see also
Explore related products
The CEA test is not useful for diagnosing or screening the general population for cancer
The CEA test is a carcinoembryonic antigen test that measures the level of CEA in the blood or other body fluids. CEA is a type of protein that unborn babies produce in the uterus, but healthy adults produce little to no CEA.
The CEA test is used to help diagnose and manage certain types of cancers, especially cancers of the large intestine and rectum. It is also used to determine whether a cancer treatment is working. Doctors use the CEA test as a "marker" to learn more about a patient's cancer. The test can help predict whether the cancer is growing or spreading to other parts of the body. It can also help determine how well a treatment has worked and predict the patient's outlook.
The CEA test is also used to establish a baseline level for a patient's CEA before they begin treatment. This baseline level is compared with levels taken during and after therapy to better understand how the cancer has responded to treatment. If CEA levels drop during treatment, it may indicate that the treatment is working. However, if CEA levels remain elevated during treatment, it may indicate that the treatment has not been successful.
In summary, while the CEA test can be useful for monitoring and managing cancer treatment, it is not suitable for diagnosing or screening the general population for cancer due to its low sensitivity and the fact that high CEA levels can be caused by various other conditions.
Oral Surgery: Dental or Medical Insurance, Which is Best?
You may want to see also
Explore related products
![100% Egyptian Cotton Sheets Split King Size | 400 Thread Count | CEA Gold Seal Certified | Ultra Soft | Cooling for Hot Sleepers | 18" Deep Pocket | Split King Size [Dune]](https://m.media-amazon.com/images/I/81ibsitjMcL._AC_UY218_.jpg)
The CEA test can be used to determine if cancer has recurred after treatment
Carcinoembryonic antigen (CEA) is a blood test used to help diagnose and manage certain types of cancers. The CEA test is used especially for cancers of the large intestine and rectum. The test measures the amount of CEA in the blood. CEA is a specific blood protein or glycoprotein that is usually produced by unborn babies in the uterus. However, some types of cancer can increase this protein.
The CEA test is used to determine if cancer treatment is working and to monitor the progress of certain treatments. It is also used to check if cancer has grown or spread (metastasized) to other parts of the body. The test is performed repeatedly before, during, and after treatment to check for changes. If CEA levels remain elevated during treatment, it may indicate that the treatment has not been successful. A rise in CEA levels four to six weeks after the start of therapy does not necessarily indicate treatment failure, relapse, or recurrence.
The test is also used to determine if cancer has returned after treatment. If CEA levels dropped during treatment but are rising again, it may indicate a recurrence of cancer. However, it is important to note that the CEA test is not used in isolation for diagnosis or screening. It is combined with physical examinations and imaging as needed. Additionally, the test is not an accurate way to detect a specific form of cancer or determine whether a patient has cancer, as many types of cancer and noncancerous conditions may cause high CEA levels.
Some insurers have added the CEA blood test to the laboratory screening profile for Life and Health insurance applications. The rationale is that a good cancer-detection tool would strengthen underwriting. However, the test has potential repercussions for applicants, including the possibility of false positives and the need for further invasive and time-consuming investigations.
Medical Bills: Post-Insurance Financial Struggles and Solutions
You may want to see also
The CEA test is capable of enough mortality reduction to yield a gain on the bottom line
Carcinoembryonic Antigen (CEA) is a protein that is a type of "tumor marker". Tumor markers are substances that are often made by cancer cells or by normal cells in response to cancer. CEA is sometimes called a tumor marker or tumor antigen. Tumor markers are substances that some cancer cells make and shed into bodily fluids at times. Healthy cells may also make tumor markers in very low levels.
A carcinoembryonic antigen (CEA) test measures CEA, a specific blood protein. Usually, people are born with high CEA levels that decrease as they get older. But some types of cancer can increase this protein. Your healthcare provider may use a CEA test to guide cancer treatment or to see if treatment is working. The test is often used with other tests to check if cancer treatment is working.
The strongest argument for any screening is avoiding anti-selection. Some people will anti-select because of known cancer or even vague concerns of ill health. You might catch them with CEA screening, but not very efficiently. Even in colon cancer, where the association with CEA is strongest, sensitivity is as low as 50%. That means half of the patients who have colon cancer have a normal CEA value.
The rationale for CEA screening is simple: a good cancer-detection tool would strengthen underwriting. The only underwriting tool that detects cancer is PSA screening in men over 50. Because of underwriting’s limited ability to screen, cancer claims predominate in the first five years of insurance policies. The promise of a CEA test is that some cancers express CEA. One insurance laboratory’s research demonstrated that elevated CEA is associated with very high mortality among insurance applicants.
Despite the increase in cost and decrease in premium, CEA is capable of enough mortality reduction to yield a gain on the bottom line. Lower mortality works if you maintain a constant premium and capture higher profit. If you lower the base premium, you have declined some applications that used to make sales, taken the rest at a lower premium, and increased your acquisition cost.
Get Medical Insurance to Greenlight Your Treatment
You may want to see also
Frequently asked questions
CEA is a carcinoembryonic antigen blood test used to help diagnose and manage certain types of cancers.
The CEA test measures the amount of CEA in the blood. A high amount of CEA in the body after cancer treatment or surgery suggests that the cancer is not gone and may have spread to other parts of the body.
The CEA test generates a different repercussion for the applicant, so potentially harmful that this alone could be a reason to not take the test. For example, a high CEA result would lead to an expensive, invasive, and time-consuming series of investigations.
The CEA test is a good cancer-detection tool that can help reduce mortality. It is especially useful after a diagnosis of a type of cancer that is known to produce CEA.
The CEA test is not useful for diagnosing or screening the general population for cancer. It is usually not used if the patient is healthy or isn't showing any symptoms of a disease. Even in colon cancer, where the association with CEA is strongest, sensitivity is as low as 50%.
